Literature DB >> 22227032

Cobalamin deficiency presenting as obsessive compulsive disorder: case report.

Vivek Sharma1, Devdutta Biswas.   

Abstract

Cobalamin deficiency commonly presents with a wide range of neuropsychiatric manifestations ranging from myelopathy, neuropathy, optic neuritis and dementia to mood disorders, chronic fatigue and psychosis even without classical hematological abnormalities like anemia and macrocytosis. However, obsessive compulsive disorder (OCD) in relation to vitamin B12 deficiency has not been described so far. We report a case of middle-aged man presenting with OCD, low serum cobalamin and a positive family history of vitamin B12 deficiency who responded well to methylcobalamin replacement.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22227032     DOI: 10.1016/j.genhosppsych.2011.11.006

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  4 in total

1.  Changes of Serum Homocysteine and Vitamin B12, but Not Folate Are Correlated With Obsessive-Compulsive Disorder: A Systematic Review and Meta-Analysis of Case-Control Studies.

Authors:  Sirui Yan; Hailong Liu; Yaqiong Yu; Nashu Han; Wenzhi Du
Journal:  Front Psychiatry       Date:  2022-05-09       Impact factor: 5.435

2.  Obsessive Compulsive Disorder due to B12 Deficiency: Justification Required.

Authors:  Suneet Kumar Upadhyaya; Archana Sharma
Journal:  Indian J Psychol Med       Date:  2012-07

3.  Roles of 5,10-methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in early- and late-onset obsessive-compulsive disorder.

Authors:  Metin Caliskan; Seda Orenay-Boyacioglu; Ayse Dondu
Journal:  Indian J Psychiatry       Date:  2019 Mar-Apr       Impact factor: 1.759

4.  Vitamin B12, folate, and homocysteine levels in patients with obsessive-compulsive disorder.

Authors:  Nuray Türksoy; Rabia Bilici; Altan Yalçıner; Y Özay Ozdemir; Ibrahim Ornek; Ali Evren Tufan; Ayşe Kara
Journal:  Neuropsychiatr Dis Treat       Date:  2014-09-09       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.